Alzamend Neuro (NASDAQ:ALZN) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Alzamend Neuro (NASDAQ:ALZN) posted its earnings results on Wednesday. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07), Zacks reports.

Alzamend Neuro Stock Performance

Shares of ALZN traded up $0.03 during trading hours on Wednesday, hitting $1.35. 70,780 shares of the company were exchanged, compared to its average volume of 138,688. The company has a market cap of $5.14 million, a PE ratio of -0.62 and a beta of 0.14. The firm’s 50 day moving average is $1.18 and its 200-day moving average is $1.52. Alzamend Neuro has a 52 week low of $0.84 and a 52 week high of $3.14.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a research note on Monday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.00.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Alzamend Neuro stock. DRW Securities LLC raised its stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) by 27.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 116,319 shares of the company’s stock after purchasing an additional 25,074 shares during the period. DRW Securities LLC owned 3.06% of Alzamend Neuro worth $212,000 as of its most recent SEC filing. 49.61% of the stock is currently owned by institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.